Acurx Pharmaceuticals, INC. (ACXP) — 10-Q Filings

10-Q Filings (6)

• Acurx Narrows Q3 Loss, But Going Concern Doubts Persist — Nov 12, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $1,992,790 for the three months ended September 30, 2025, an improvement from a net loss of $2,821,597
• Acurx Pharmaceuticals Burns Cash, Eyes Partnerships Amidst Warrant Dilution — Aug 11, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company i
• Acurx Pharmaceuticals Q1 2025: Net Loss Narrows to $17.03M — May 12, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported a net loss of $17.03 million for the three mon
• Acurx Pharmaceuticals Q3 2024 Update — Nov 12, 2024 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its quarterly report for the period ending September 30, 2024. The company reported total assets of $16,770,378 and total liab
• Acurx Pharmaceuticals Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Acurx Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. (ACXP) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Acurx Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX